2-acetylamino-3-nitro-benzoic acid | 90417-80-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-acetylamino-3-nitro-benzoic acid
• 英文别名: 2-Acetylamino-3-nitro-benzoesaeure；3-Nitro-2-acetamino-benzoesaeure；N-Acetyl-3-nitro-anthranilsaeure；2-Acetamido-3-nitrobenzoesaeure；5-Nitroacetanthranilsaeure；2-Acetamido-3-nitrobenzoic acid
• CAS: 90417-80-4
• 化学式: C₉H₈N₂O₅
• 分子量: 224.173
• InChiKey: YLXNPMSVXYVEHU-UHFFFAOYSA-N

物化性质

• 熔点：
  214 °C
• 沸点：
  481.2±40.0 °C(Predicted)
• 密度：
  1.526±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-acetylamino-3-nitro-benzoic acid 在 硫酸 作用下， 生成 2-氨基-3-硝基苯甲酸
  参考文献：
  名称：

  James; Kenner; Stubbings, Journal of the Chemical Society, 1920, vol. 117, p. 775

  摘要：

  DOI：
• 作为产物：
  描述：

  N-(2-甲基-6-硝基苯基)-乙酰胺 在 permanganate(VII) ion 、 magnesium sulfate 作用下， 生成 2-acetylamino-3-nitro-benzoic acid
  参考文献：
  名称：

  James; Kenner; Stubbings, Journal of the Chemical Society, 1920, vol. 117, p. 775

  摘要：

  DOI：

文献信息

• Aromatic amino acid derivates and medicinal compositions
  申请人：Endo Hitoshi

  公开号：US20050119256A1

  公开（公告）日：2005-06-02

  1. An aromatic amino acid derivative represented by the formula (I) or its pharmacologically acceptable salt: wherein, R 1 is a hydrogen atom or an amino-protecting group, R 2 is a halogen atom or an alkyl, aralkyl or aryl group, R 3 is circle over (1)} a hydrogen atom, circle over (2)} an aroylamino group, circle over (3)} a phenyl group substituted with lower alkyl, phenyl, phenoxy, etc. circle over (4)} a naphthyl or tetrahydronaphthyl group optionally substituted with hydroxy, lower alkoxy or di(lower)alkylamino, circle over (5)} an unsaturated mono-cyclic heterocyclic group containing N, O and/or S substituted with lower alkyl, phenyl, naphthyl or tetrahydroquinolyl, circle over (6)} an unsaturated or partially saturated condensed heterocyclic group containing N, O and/or S, optionally substituted with oxo, carboxy, amino, lower alkyl, etc.; X is a halogen atom, an alkyl group or an alkoxy group; Y is oxygen atom or nitrogen atom; I is 0 or 1; m is 0, 1 or 2; n is an integer of 0-5. This compound can inhibit a transporter (LAT1) of essential amino acid which is one of main nutrition for cancer cells and accordingly cause drain of the essential amino acid on the cancer cells and finally can prohibit the multiplication of cancer cells.

  一种芳香族氨基酸衍生物，其化学式为（I）或其药理学上可接受的盐：其中，R1为氢原子或氨基保护基；R2为卤素原子或烷基、芳基烷基或芳基基团；R3为circle over (1)}氢原子，circle over (2)}芳基氨基基团，circle over (3)}苯基，其取代基为较低的烷基、苯基、苯氧基等，circle over (4)}萘基或四氢萘基，可选地取代羟基、较低的烷氧基或二（较低）烷基氨基，circle over (5)}含N、O和/或S的不饱和单环杂环基团，取代基为较低的烷基、苯基、萘基或四氢喹啉基团，circle over (6)}含N、O和/或S的不饱和或部分饱和的紧缩杂环基团，可选地取代为氧代、羧基、氨基、较低的烷基等；X为卤素原子、烷基或烷氧基；Y为氧原子或氮原子；I为0或1；m为0、1或2；n为0-5的整数。该化合物可以抑制癌细胞的主要营养物质之一的必需氨基酸转运体（LAT1），从而导致癌细胞必需氨基酸的流失，最终可以抑制癌细胞的增殖。
• BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Koike Tatsuki

  公开号：US20100130538A1

  公开（公告）日：2010-05-27

  The present invention provides a compound represented by the formula wherein R 1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s); R 2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); Xa and Xb are each C, N, O or S; Xc and Xd are each C or N; m is 0-2; n is 1-3; ring A is a 5-membered ring optionally having substituent(s); ring B is a 6-membered ring optionally having substituent(s); and ring C is a 3- to 5-membered ring optionally having substituent(s), provided that when Xa, Xc and Xd are each C, then Xb is N or S, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.

  本发明提供了一种化合物，其表示式为其中R1是一个烃基，可选地具有取代基，氨基，可选地具有取代基的羟基或杂环基；R2是氢原子或烃基，可选地具有取代基；Xa和Xb分别为C，N，O或S；Xc和Xd分别为C或N；m为0-2；n为1-3；环A是一个五元环，可选地具有取代基；环B是一个六元环，可选地具有取代基；环C是一个3-至5元环，可选地具有取代基，前提是当Xa，Xc和Xd均为C时，那么Xb为N或S，或其盐，用作预防或治疗与褪黑素作用相关的疾病的药剂等。
• Anticancer agent composition
  申请人：J-Pharma Co., Ltd.

  公开号：US10172835B2

  公开（公告）日：2019-01-08

  A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

  一种治疗癌症的方法包括向需要治疗的受试者施用抗癌剂组合物，该组合物包括作为活性成分的下列制剂；LAT1抑制剂，以及选自以下组别的一种或多种制剂：烷化剂、铂类抗肿瘤剂、抗代谢剂、拓扑异构酶抑制剂、抗微管聚合剂、激素制剂、抗微管解聚剂、抗癌抗生素和分子靶向制剂。
• Ajello, Gazzetta Chimica Italiana, 1940, vol. 70, p. 401,403
  作者：Ajello

  DOI：——

  日期：——
• ANTI-MALIGNANT TUMOR AGENT COMPOSITION
  申请人：J-Pharma Co., Ltd.

  公开号：EP2959918B1

  公开（公告）日：2019-05-22